Acadia Pharmaceuticals
ACAD
234 hedge funds and large institutions have $3.75B invested in Acadia Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 91 increasing their positions, 76 reducing their positions, and 22 closing their positions.
36% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 22
20% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 76
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
3% more funds holding
Funds holding: 228 → 234 (+6)
4% more capital invested
Capital invested by funds: $3.61B → $3.75B (+$141M)
3% less call options, than puts
Call options by funds: $41.1M | Put options by funds: $42.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$44.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$29.6M |
| 4 |
Goldman Sachs
New York
|
+$28.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$28.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$34.8M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$15.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.4M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$8.54M |
| 5 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
-$7.93M |
ACAD Hedge Fund Activity: Q3 2016 in Review
234 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2016, worth a combined $3.75B — up 3.9% from $3.61B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ACAD positions and 22 closed out — a net gain of 8 holders — while 91 added to existing stakes and 76 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $44.2M. The largest seller was Lord, Abbett & Co, cutting an estimated $34.8M.
- 234 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2016, up from 228 in Q2 2016.
- Funds reported $3.75B of Acadia Pharmaceuticals stock for Q3 2016, up 3.9% quarter-over-quarter.
- 30 funds opened new Acadia Pharmaceuticals positions in Q3 2016 and 22 closed out, a net change of +8 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2016 was Baker Bros. Advisors, an estimated $44.2M added.
- The largest Acadia Pharmaceuticals seller in Q3 2016 was Lord, Abbett & Co, an estimated $34.8M sold.
Based on aggregated 13F filings for Q3 2016.